Medical marijuana—an obesity problem or opportunity?

@article{Greenway2019MedicalMO,
  title={Medical marijuana—an obesity problem or opportunity?},
  author={Frank L. Greenway and John P. Kirwan},
  journal={International Journal of Obesity},
  year={2019},
  volume={43},
  pages={761-762}
}
Marijuana for medical or recreational use is now legal in 33 of the 50 United States (US) and in the District of Columbia. Since marijuana had previously been illegal, and still is at the federal level, marijuana research has been limited with a few notable exceptions. On the surface, one might assume that marijuana would only exacerbate the obesity epidemic as increased appetite is a well-known side effect; however, initial obesity research suggests that this assumption may be premature… 

Cannabis sativa as a Treatment for Obesity: From Anti-Inflammatory Indirect Support to a Promising Metabolic Re-Establishment Target.

Phytocannabinoids derived from Cannabis sativa have therapeutic potential due to its anti-inflammatory, antioxidant, and neuroprotective properties, making the plant a study option to reduce and reverse inflammation and comorbidities associated with obesity.

Cloudy with a Chance of Munchies: Assessing the Impact of Recreational Marijuana Legalization on Obesity Using a Synthetic Control Approach

Obesity in the US arguably constitutes the most significant health epidemic over the past century. Recent legislative changes allowing for recreational marijuana use further create a need to better

References

SHOWING 1-10 OF 11 REFERENCES

Rimonabant: From RIO to Ban

This paper provides a brief overview of the Rimonabant story and places the recent spate of FDA rejections of other centrally acting weight loss drugs entering Phase 3 trials in this context.

Neural Effects of Cannabinoid CB1 Neutral Antagonist Tetrahydrocannabivarin on Food Reward and Aversion in Healthy Volunteers

Treatment with the CB1 neutral antagonist tetrahydrocannabivarin increases neural responding to rewarding and aversive stimuli, suggesting therapeutic activity in obesity, perhaps with a lowered risk of depressive side effects.

The cannabinoid Δ9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity

THCV dose-dependently reduced glucose intolerance in ob/ob mice and improved glucose tolerance and increased insulin sensitivity in DIO mice, without consistently affecting plasma lipids.

Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study

CBD and THCV could represent a new therapeutic agent in glycemic control in subjects with type 2 diabetes and were well tolerated.

Dysregulation of the Peripheral and Adipose Tissue Endocannabinoid System in Human Abdominal Obesity

The findings suggest that abdominal fat accumulation is a critical correlate of the dysregulation of the peripheral endocannabinoid system in human obesity and may represent a primary target for the treatment of abdominal obesity and associated metabolic changes.

Synthetic and plant‐derived cannabinoid receptor antagonists show hypophagic properties in fasted and non‐fasted mice

This data indicates that suppression of Cannabinoid receptors in the central nervous mechanisms underlying food‐seeking behaviour and reward are at the forefront of medical research and may have implications for obesity.

Cannabivarin and Tetrahydrocannabivarin, Two New Constituents of Hashish

THE AUTHORS have identified two more constituents of hashish to add to the constituents of Hashish already known, including a Δ1-tetrahydrocannabinol homologue with C3H7, instead of C5H11 as the side chain.

Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ9‐tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats

Two phytocannabinoids are evaluated, cannabidivarin (CBDV) and Δ9‐tetrahydrocannabvarin (THCV), for their ability to produce these behavioural effect characteristics of CB1 receptor inverse agonism in rats.

Evidence that the plant cannabinoid Δ9‐tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist

In the vas deferens, THCV antagonized several cannabinoids more potently than THC and was also more potent against CP55940 and R‐(+)‐WIN55212 in this tissue than in brain membranes, behaving as a competitive CB1 and CB2 receptor antagonist.

The psychoactive plant cannabinoid, Δ9‐tetrahydrocannabinol, is antagonized by Δ8‐ and Δ9‐tetrahydrocannabivarin in mice in vivo

To follow up in vitro evidence that Δ9‐tetrahydrocannabivarin extracted from cannabis is a CB1 receptor antagonist, a study is conducted to establish whether synthetic Δ9.9.4% and Δ8.8.3% Δ9/8.2% cannabinoids behave as CB1 antagonists in vivo.